Study of the effects of Elaeagnus angustifolia L. fruit on the profile of hormones and lipids and genital infectious in menopausal women

Study of the effects of Elaeagnus angustifolia L. fruit on the profile of hormones and lipids and genital infectious in menopausal women refer to Kamali hospital in 1396

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170227032795N4

Enrollment

120

Registered

2018-07-26

Start date

2017-08-05

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopause. Menopausal and perimenopausal disorder, unspecified.

Interventions

Intervention 1: Intervention group: Elaeagnus angustifolia L powder, 15 g / day longer 10 weeks. Intervention 2: Control group(placebo):7.5 g isomalt and 7.5 g corn starch longer 10 weeks.

Eligibility

Sex/Gender

Female

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Postmenopausal women aged 40-70. Serum lipid level of 200-300 mg / ml. No risk factor for using the drug to lower this lipid level.

Exclusion criteria

Exclusion criteria: Cardiovascular diseases. Renal diseases. Metabolic disorders such as diabetes. Those using psychiatric drugs. Having destructive habits like cigarettes, hookahs, consuming alcohol and drugs.

Design outcomes

Primary

Measure	Time frame
FBS(Fasting blood sugar). Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;LDL. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;HDL. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Triglyceride. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Insulin. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;HbA1c. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Blood pressure. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Total Protein. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Estradiol. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Progesterone. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Testosterone. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;FSH (Follicle stimulating hormone). Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of mea	—

Measure

Time frame

FBS(Fasting blood sugar). Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;LDL. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;HDL. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Triglyceride. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Insulin. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;HbA1c. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Blood pressure. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Total Protein. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Estradiol. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Progesterone. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;Testosterone. Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of measurement: Standards of medical diagnostic laboratories.;FSH (Follicle stimulating hormone). Timepoint: Before the start of the trial and 10 weeks after taking the drug or placebo. Method of mea

—

Secondary

Measure	Time frame
Constipation, Abdominal Pain. Timepoint: End of the course after 10 weeks. Method of measurement: Standards of medical diagnostic laboratories.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Emami Nia

University of Damghan

Farzaneh.Emaminia@gmail.com+98 22001395

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 15, 2026